Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCRX

DatePrice TargetRatingAnalyst
2/25/2025$15.00Outperform
Wedbush
11/20/2023$10.00Overweight
JP Morgan
9/18/2023$9.00 → $10.00Sector Perform → Outperform
RBC Capital Mkts
8/4/2023$11.00Hold → Buy
Jefferies
7/13/2023$10.00Neutral → Buy
BofA Securities
2/22/2023$14.00Hold → Buy
Needham
11/2/2022$14.00 → $16.00In-line → Outperform
Evercore ISI
8/5/2022Outperform → Perform
Oppenheimer
More analyst ratings

$BCRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • BioCryst to Present at Upcoming Investor Conference

    RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design t

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the com

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

    —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$BCRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BCRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCRX
SEC Filings

See more

$BCRX
Leadership Updates

Live Leadership Updates

See more
  • BioCryst Appoints Dr. Donald Fong Chief Medical Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company's new chief medical officer, effective immediately. Dr. Fong joins Dr. Helen Thackray, the company's chief research and development officer, and Dr. Bill Sheridan, the company's chief development officer, as physicians on the company's leadership team. "We continue to advance our pipeline of novel therapies to treat diseases with significant unmet needs, including programs in Netherton syndrome and diabetic macular edema that we expect will enter the clinic this year and next year, respectively. Dona

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

    RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. "I am honored to succeed Bob Ingram. He was a model of effective board leadership for us. Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to patients with rare diseases," said Dr. Hutson. Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutica

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company's significant pipeline of development candidates. Dr. Ryan Arnold has been appointed as the company's new chief medical officer. Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the company's chief research and development officer, as physicians on the company's leadership team. "Our research and development platform continues to generate exciting opportunities across multiple rare disease targets and Bill's deep knowledge of our portfolio and dedicated focus on our pipelin

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$BCRX
Financials

Live finance-specific insights

See more
  • BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

    —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

    RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a gl

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

    — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating profit of $7.7 million in third quarter ($24.9 million non-GAAP operating profit) — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the third quarter ended September 30, 2024, and p

    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$BCRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more